Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Bullboard Posts
Post by somweyungguyon Sep 19, 2016 10:17pm
136 Views
Post# 25254402

The Beech Boys are selling "long 2 weeks"

The Beech Boys are selling "long 2 weeks"What for ( cause they're asked to ) but really WHY?

The interim data signaled at 12% absolute efficacy at 600 patients ( 650 was settled upon )

The knowledgeable GMP analyst suggests 10% is the downside and values the stock at $1

He also states that 15% would drive a $3 share price.

12% = $1.75 and is the floor

The chosen 176 patients ( 2nd page of Spetember 2015 NR ) yeah, 2nd page! Backs a 20$ expected absolute efficacy.  Any suggestion of a sub 20% absolute benefit would have seen the FDA call for additional patients.


These shares must be more valuable than I imagined given the decade long fairy tale told here.

Sqr
Bullboard Posts